These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

861 related articles for article (PubMed ID: 32150314)

  • 21. Uncovering Unrecognized Heart Failure With Preserved Ejection Fraction Among Individuals With Obesity and Dyspnea.
    Kosyakovsky LB; Liu EE; Wang JK; Myers L; Parekh JK; Knauss H; Lewis GD; Malhotra R; Nayor M; Robbins JM; Gerszten RE; Hamburg NM; McNeill JN; Lau ES; Ho JE
    Circ Heart Fail; 2024 May; 17(5):e011366. PubMed ID: 38742409
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved ejection fraction (CAPACITY HFpEF).
    Udelson JE; Lewis GD; Shah SJ; Zile MR; Redfield MM; Burnett J; Mittleman RS; Profy AT; Seferovic JP; Reasner D; Konstam MA
    Am Heart J; 2020 Apr; 222():183-190. PubMed ID: 32105984
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial.
    Kosiborod MN; Verma S; Borlaug BA; Butler J; Davies MJ; Jon Jensen T; Rasmussen S; Erlang Marstrand P; Petrie MC; Shah SJ; Ito H; Schou M; Melenovský V; Abhayaratna W; Kitzman DW;
    Circulation; 2024 Jan; 149(3):204-216. PubMed ID: 37952180
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of exercise training on cardiac function, exercise capacity, and quality of life in heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trials.
    Fukuta H; Goto T; Wakami K; Kamiya T; Ohte N
    Heart Fail Rev; 2019 Jul; 24(4):535-547. PubMed ID: 31032533
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resting ventricular-vascular function and exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study.
    Mohammed SF; Borlaug BA; McNulty S; Lewis GD; Lin G; Zakeri R; Semigran MJ; LeWinter M; Hernandez AF; Braunwald E; Redfield MM
    Circ Heart Fail; 2014 Jul; 7(4):580-9. PubMed ID: 24833648
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Highest Obesity Category Associated With Largest Decrease in N-Terminal Pro-B-Type Natriuretic Peptide in Patients Hospitalized With Heart Failure With Preserved Ejection Fraction.
    Vaishnav J; Chasler JE; Lee YJ; Ndumele CE; Hu JR; Schulman SP; Russell SD; Sharma K
    J Am Heart Assoc; 2020 Aug; 9(15):e015738. PubMed ID: 32750299
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rationale and design of the EMPERIAL-Preserved and EMPERIAL-Reduced trials of empagliflozin in patients with chronic heart failure.
    Abraham WT; Ponikowski P; Brueckmann M; Zeller C; Macesic H; Peil B; Brun M; Ustyugova A; Jamal W; Salsali A; Lindenfeld J; Anker SD;
    Eur J Heart Fail; 2019 Jul; 21(7):932-942. PubMed ID: 31218819
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the RELAX trial.
    DeVore AD; McNulty S; Alenezi F; Ersboll M; Vader JM; Oh JK; Lin G; Redfield MM; Lewis G; Semigran MJ; Anstrom KJ; Hernandez AF; Velazquez EJ
    Eur J Heart Fail; 2017 Jul; 19(7):893-900. PubMed ID: 28194841
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The neurohormonal basis of pulmonary hypertension in heart failure with preserved ejection fraction.
    Obokata M; Kane GC; Reddy YNV; Melenovsky V; Olson TP; Jarolim P; Borlaug BA
    Eur Heart J; 2019 Dec; 40(45):3707-3717. PubMed ID: 31513270
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial.
    Armstrong PW; Lam CSP; Anstrom KJ; Ezekowitz J; Hernandez AF; O'Connor CM; Pieske B; Ponikowski P; Shah SJ; Solomon SD; Voors AA; She L; Vlajnic V; Carvalho F; Bamber L; Blaustein RO; Roessig L; Butler J;
    JAMA; 2020 Oct; 324(15):1512-1521. PubMed ID: 33079152
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identifying a low-flow phenotype in heart failure with preserved ejection fraction: a secondary analysis of the RELAX trial.
    Patel KV; Mauricio R; Grodin JL; Ayers C; Fonarow GC; Berry JD; Pandey A
    ESC Heart Fail; 2019 Aug; 6(4):613-620. PubMed ID: 30993916
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amount or intensity? Potential targets of exercise interventions in patients with heart failure with preserved ejection fraction.
    Bobenko A; Bartels I; Münch M; Trippel T; Lindhorst R; Nolte K; Herrmann-Lingen C; Halle M; Duvinage A; Düngen HD; Gelbrich G; Tschöpe C; Hasenfuss G; Wachter R; Pieske B; Edelmann F
    ESC Heart Fail; 2018 Feb; 5(1):53-62. PubMed ID: 29210202
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regional Adipose Distribution and its Relationship to Exercise Intolerance in Older Obese Patients Who Have Heart Failure With Preserved Ejection Fraction.
    Haykowsky MJ; Nicklas BJ; Brubaker PH; Hundley WG; Brinkley TE; Upadhya B; Becton JT; Nelson MD; Chen H; Kitzman DW
    JACC Heart Fail; 2018 Aug; 6(8):640-649. PubMed ID: 30007558
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Association With Exercise Capacity, Left Ventricular Filling Pressures, Natriuretic Peptides, and Left Atrial Volume.
    Lam CS; Rienstra M; Tay WT; Liu LC; Hummel YM; van der Meer P; de Boer RA; Van Gelder IC; van Veldhuisen DJ; Voors AA; Hoendermis ES
    JACC Heart Fail; 2017 Feb; 5(2):92-98. PubMed ID: 28017355
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Semaglutide and NYHA Functional Class in Obesity-Related Heart Failure With Preserved Ejection Fraction: The STEP-HFpEF Program.
    Schou M; Petrie MC; Borlaug BA; Butler J; Davies MJ; Kitzman DW; Shah SJ; Verma S; Patel S; Chinnakondepalli KM; Harring S; Abildstrøm SZ; Liisberg K; Kosiborod MN;
    J Am Coll Cardiol; 2024 Jul; 84(3):247-257. PubMed ID: 38913004
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of mineralocorticoid receptor antagonists on left ventricular diastolic function, exercise capacity, and quality of life in heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trials.
    Fukuta H; Goto T; Wakami K; Kamiya T; Ohte N
    Heart Vessels; 2019 Apr; 34(4):597-606. PubMed ID: 30315496
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cardiopulmonary exercise testing reflects similar pathophysiology and disease severity in heart failure patients with reduced and preserved ejection fraction.
    Guazzi M; Labate V; Cahalin LP; Arena R
    Eur J Prev Cardiol; 2014 Jul; 21(7):847-54. PubMed ID: 23382540
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Different determinants of exercise capacity in HFpEF compared to HFrEF.
    Batalli A; Ibrahimi P; Bytyçi I; Ahmeti A; Haliti E; Elezi S; Henein MY; Bajraktari G
    Cardiovasc Ultrasound; 2017 Apr; 15(1):12. PubMed ID: 28446199
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rationale and Design of the VITALITY-HFpEF Trial.
    Butler J; Lam CSP; Anstrom KJ; Ezekowitz J; Hernandez AF; O'Connor CM; Pieske B; Ponikowski P; Shah SJ; Solomon SD; Voors AA; Wu Y; Carvalho F; Bamber L; Blaustein RO; Roessig L; Armstrong PW
    Circ Heart Fail; 2019 May; 12(5):e005998. PubMed ID: 31096775
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.
    Redfield MM; Chen HH; Borlaug BA; Semigran MJ; Lee KL; Lewis G; LeWinter MM; Rouleau JL; Bull DA; Mann DL; Deswal A; Stevenson LW; Givertz MM; Ofili EO; O'Connor CM; Felker GM; Goldsmith SR; Bart BA; McNulty SE; Ibarra JC; Lin G; Oh JK; Patel MR; Kim RJ; Tracy RP; Velazquez EJ; Anstrom KJ; Hernandez AF; Mascette AM; Braunwald E;
    JAMA; 2013 Mar; 309(12):1268-77. PubMed ID: 23478662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.